Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torben Harsløf

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Medical treatment of osteoporotic vertebral fracturesBente Lomholt Langdahl, Torben Harsløf
Current Opinion in Pharmacology|March 19, 2016
New horizons in osteoporosis therapiesTorben Harsløf, Bente L Langdahl
Endocrine|February 22, 2019
Huge variations in definition and reported incidence of postsurgical hypoparathyroidism: a systematic reviewTorben Harsløf, Lars Rolighed, Lars Rejnmark
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 4, 2021
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized StudyAnne Sophie Sølling, Torben Harsløf, Bente Langdahl
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 28, 2020
Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized TrialAnne Sophie Sølling, Torben Harsløf, Bente Langdahl
Clinical Endocrinology|April 12, 2019
T-score differences and nonprogression in lumbar vertebrae as predictors of vertebral fracturesSiv E Lajlev, Lars Rejnmark, Torben Harsløf
Calcified Tissue International|October 6, 2023
The Effect of Effervescent and Buffered Alendronate Compared to Conventional Alendronate on Markers of Bone Turnover: A Randomized Non-inferiority TrialRawan Hikmet, Torben Harsløf, Bente Lomholt Langdahl
Drugs & Aging|May 9, 2019
Current Status of Bone-Forming Therapies for the Management of OsteoporosisAnne Sophie Koldkjær Sølling, Torben Harsløf, Bente Langdahl
Endocrine|September 7, 2023
Bone turnover decreases and bone structure improves during treatment with weekly high-dose methylprednisolone for 12 weeks in Graves' orbitopathyTorben Harsløf, Rawan Hikmet, Eva Ebbehøj, et al.
Therapeutic Advances in Musculoskeletal Disease|June 27, 2018
The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosisAnne Sophie Koldkjær Sølling, Torben Harsløf, Bente Langdahl
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Therapeutic Advances in Musculoskeletal Disease|August 8, 2012
Medical treatment of osteoporotic vertebral fracturesBente Lomholt Langdahl, Torben Harsløf
Current Opinion in Pharmacology|March 19, 2016
New horizons in osteoporosis therapiesTorben Harsløf, Bente L Langdahl
Endocrine|February 22, 2019
Huge variations in definition and reported incidence of postsurgical hypoparathyroidism: a systematic reviewTorben Harsløf, Lars Rolighed, Lars Rejnmark
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 4, 2021
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized StudyAnne Sophie Sølling, Torben Harsløf, Bente Langdahl
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 28, 2020
Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized TrialAnne Sophie Sølling, Torben Harsløf, Bente Langdahl
Clinical Endocrinology|April 12, 2019
T-score differences and nonprogression in lumbar vertebrae as predictors of vertebral fracturesSiv E Lajlev, Lars Rejnmark, Torben Harsløf
Calcified Tissue International|October 6, 2023
The Effect of Effervescent and Buffered Alendronate Compared to Conventional Alendronate on Markers of Bone Turnover: A Randomized Non-inferiority TrialRawan Hikmet, Torben Harsløf, Bente Lomholt Langdahl
Drugs & Aging|May 9, 2019
Current Status of Bone-Forming Therapies for the Management of OsteoporosisAnne Sophie Koldkjær Sølling, Torben Harsløf, Bente Langdahl
Endocrine|September 7, 2023
Bone turnover decreases and bone structure improves during treatment with weekly high-dose methylprednisolone for 12 weeks in Graves' orbitopathyTorben Harsløf, Rawan Hikmet, Eva Ebbehøj, et al.
Therapeutic Advances in Musculoskeletal Disease|June 27, 2018
The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosisAnne Sophie Koldkjær Sølling, Torben Harsløf, Bente Langdahl
Pageof 5